Sentences and paragraphs of JBL's Risk Factors and MD&A, 10-K 2026-10-23 against 10-K 2025-10-17.
Each links to the text at sec.gov.
Show the other 37
RewordedRisk Factors
We cannot determine in advance the extent to which some jurisdictions may assess additional tax taxes, interest, or interest and penalties on such additional taxes. penalties.
Read it in 10-K 2026-10-23 at sec.gov ↗
RewordedRisk Factors
We are subject to litigation and proceedings, which may result have resulted in substantial expenses, settlement costs, or judgments; require required the time and attention of key management resources; and result and/or resulted in adverse publicity, any of which may negatively impact our financial performance.
Read it in 10-K 2026-10-23 at sec.gov ↗
RewordedRisk Factors
Defects in the products we manufacture or design, whether caused by a design, manufacturing manufacturing, process or component failure or error, or deficiencies in our manufacturing processes, have occurred and may result resulted in delayed shipments to customers or reduced or canceled customer orders.
Read it in 10-K 2026-10-23 at sec.gov ↗
RewordedRisk Factors
We base our tax position upon positions on the anticipated nature and conduct of our business and upon our understanding of the tax laws of the various countries in which we have assets or conduct activities.
Read it in 10-K 2026-10-23 at sec.gov ↗
RewordedRisk Factors
Our tax position, however, is positions are subject to review and possible challenge by taxing authorities (including application of transfer pricing rules to our intercompany transactions) and to possible changes in law.
Read it in 10-K 2026-10-23 at sec.gov ↗
Quiet changesRisk Factors
Most Many of our customers do not commit to firm production schedules for more than one quarter.
Read it in 10-K 2026-10-23 at sec.gov ↗
Quiet changesRisk Factors
Because we make capital expenditures during this ramping-up process and do may not receive payment until after we produce and ship the customer’s products, any delays or unanticipated costs in the ramping-up process have, and may again have, a significant adverse effect on our cash flows and our results of operations.
Read it in 10-K 2026-10-23 at sec.gov ↗
Quiet changesRisk Factors
Regardless of the merits of the claims, litigation or governmental proceedings may be are both time-consuming and disruptive to our business.
Read it in 10-K 2026-10-23 at sec.gov ↗
AddedMD&A
We are one of the leading providers of engineering, supply chain, and manufacturing solutions. We deliver comprehensive design, production, and product management services to companies across a diverse range of industries and end markets. Our capabilities span the entire product lifecycle—from innovation, design, and planning to fabrication, assembly, delivery, and post-production— enabling seamless management of resources and materials across global supply chains. Through these integrated services, we help our customers reduce manufacturing costs, enhance supply chain efficiency, minimize inventory risk, lower transportation expenses, and accelerate product fulfillment.
Read it in 10-K 2026-10-23 at sec.gov ↗
AddedMD&A
Beginning September 1, 2026, our Connected Living and Digital Commerce segment was renamed to Intelligent Devices and Robotics to better reflect the evolution of the business, including our increased emphasis on automation and robotic capabilities and a strategic shift towards more highly complex, engineered solutions. Our Intelligent Devices and Robotics segment is focused on digitalization and automation, including warehouse automation and robotics, and includes revenues from customers primarily in the connected living and digital commerce and robotics industries. The name change did not impact the composition of the Company's reportable segments or the financial information reported for those segments.
Read it in 10-K 2026-10-23 at sec.gov ↗
AddedMD&A
On February 20, 2026, the U.S. Supreme Court issued a ruling striking down tariffs imposed under the International Emergency Economic Powers Act (“IEEPA”), including, among others, tariffs on imports of certain Canadian, Chinese, and Mexican goods, a universal baseline tariff on imports from most countries, and reciprocal tariffs on select countries. On April 20, 2026, the U.S. Customs and Border Protection launched a system to process IEEPA tariff refund claims. The Company recognizes refunds in the Consolidated Financial Statements as and when the amounts are probable and reasonably estimable. During the fiscal year ended August 31, 2026, the Company began receiving refunds for IEEPA tariffs previously paid, which did not have a material impact on the Company’s results of operations. The global tariff landscape continues to shift rapidly, with changes impacting businesses and markets around the world. We continue to monitor the situation, including whether any additional refunds may be forthcoming, and we do not expect that the receipt of any additional refunds would have a material impact on the Company’s results of operations.
Read it in 10-K 2026-10-23 at sec.gov ↗
AddedMD&A
On August 27, 2026, we received an FDA Warning Letter relating to an inspection in March 2026 of the Pharmaceutics International, Inc. (“Pii”) facility in Hunt Valley, Maryland. The letter includes findings related to manufacturing practices and quality systems. All findings relate to Pii and that location, and we do not conduct aseptic filling at any other Jabil location. Since the inspection, management has paused manufacturing at the site, made leadership changes, and launched a comprehensive corrective action plan supported by Jabil’s quality, technical, and operational resources, as well as external industry experts. We are working constructively with the FDA as we address the findings and will begin full remediation once the plan is approved.
Read it in 10-K 2026-10-23 at sec.gov ↗
AddedMD&A
(1)On January 23, 2026, we issued $500 million aggregate principal amount of 4.200% Senior Notes due 2029 (the “4.200% Senior Notes”) and $500 million aggregate principal amount of 4.750% Senior Notes due 2033 (the “4.750% Senior Notes”) in an underwritten public offering. We used the net proceeds for general corporate purposes, including the repayment of the $500 million aggregate principal amount of 1.700% Senior Notes due in April 2026.
Read it in 10-K 2026-10-23 at sec.gov ↗
RemovedMD&A
We are one of the leading providers of worldwide manufacturing services and solutions. We provide comprehensive electronics design, production, and product management services to companies in various industries and end markets. We derive substantially all of our revenue from production and product management services (collectively referred to as “manufacturing services”), which encompass the act of producing tangible components that are built to customer specifications and are then provided to the customer.
Read it in 10-K 2025-10-17 at sec.gov ↗
RemovedMD&A
Beginning in February 2025, the U.S. implemented tariffs on a variety of countries and commodities, including, among others, tariffs on aluminum and steel derivative products, imports of certain Canadian and Mexican goods, imports of Chinese goods, universal tariffs on imports from most countries, and reciprocal tariffs on select countries. In response, certain countries have imposed, or are considering, retaliatory tariffs on U.S. exports. The global tariff landscape continues to shift rapidly, with changes impacting businesses and markets around the world. While these increased tariffs have and may continue to impact end customer demand, we expect that we will recover the tariff costs by passing them on to our customers. If we are unable to fully pass on these costs, our operating results and cash flows could be adversely impacted.
Read it in 10-K 2025-10-17 at sec.gov ↗
RemovedMD&A
in the fair market value of such hedging instruments are reflected within the Consolidated Statements of Operations and the Consolidated Statements of Comprehensive Income.
Read it in 10-K 2025-10-17 at sec.gov ↗
RemovedMD&A
(1)Decrease from prior periods was primarily driven by domestic revenue growth within our Intelligent Infrastructure segment during the fiscal year ended August 31, 2025 and the divestiture of the Mobility Business during the fiscal year ended August 31, 2024.
Read it in 10-K 2025-10-17 at sec.gov ↗
RemovedMD&A
We expect to recognize approximately $200 million in pre-tax restructuring and other related costs related to the 2025 Restructuring Plan. The restructuring and other related charges are expected to include $60 million to $70 million of employee severance and benefit costs; $65 million to $70 million of asset write-off costs; and $55 million to $65 million of contract termination costs and other related costs. The amount and timing of the actual charges may vary due to a variety of factors, including the finalization of timetables for the transition of functions, consultation with employees and their representatives, as well as the impact of jurisdictional statutory severance requirements. Our estimates for the charges discussed above exclude any potential income tax effects.
Read it in 10-K 2025-10-17 at sec.gov ↗
RemovedMD&A
Prior to fiscal year 2023, the Company determined the tax effect of the items included and excluded from core earnings quarterly.
Read it in 10-K 2025-10-17 at sec.gov ↗
RemovedMD&A
(2)Pension service cost is recognized in cost of revenue and all other components of net periodic benefit cost, including return on plan assets, are presented in other expense. We are reclassifying the pension components in other expense to core operating income as we assess operating performance, inclusive of all components of net periodic benefit cost, with the related revenue. There is no impact to core earnings or diluted core earnings per share for this adjustment.
Read it in 10-K 2025-10-17 at sec.gov ↗
RemovedMD&A
(1)Certain customers co-invest in PP&E with us. As we acquire PP&E, we recognize the cash payments in acquisition of PP&E. When our customers reimburse us and obtain control, we recognize the cash receipts in proceeds and advances from the sale of PP&E.
Read it in 10-K 2025-10-17 at sec.gov ↗
RemovedMD&A
On September 1, 2025, we completed the acquisition of Rebound Technologies Group Holdings Limited (“Rebound Technologies”) for cash consideration transferred of $134 million. Rebound Technologies is a global supply chain service provider headquartered in the United Kingdom offering end-to-end solutions including global sourcing, data driven analytics, proactive shortage management and obsolescence strategies. The final purchase price is subject to adjustment based on conditions within the purchase agreement.
Read it in 10-K 2025-10-17 at sec.gov ↗
RemovedMD&A
On February 3, 2025, we completed the acquisition of Pharmaceutics International, Inc. (“Pii”) for cash consideration transferred of $309 million. The final purchase price is subject to adjustment based on certain customary conditions as outlined in the purchase agreement. Pii is a contract development and manufacturing organization specializing in early stage, clinical, and commercial volume aseptic filling, lyophilization, and oral solid dose manufacturing. The acquisition is expected to enhance our existing Regulated Industries service offerings, which includes the development and commercial production of auto-injectors, pen injectors, inhalers, and on-body pumps.
Read it in 10-K 2025-10-17 at sec.gov ↗
RemovedMD&A
The acquisition of Pii was accounted for as a business combination using the acquisition method of accounting. Assets acquired of $357 million, including $149 million in intangible assets and $142 million in goodwill, and liabilities assumed of $48 million were recorded at their estimated fair values as of the acquisition date. The preliminary estimates and measurements are subject to change during the measurement period for assets acquired, liabilities assumed, and tax adjustments. The excess of the purchase price over the fair value of the acquired assets and assumed liabilities was recorded to goodwill and was fully allocated to the Regulated Industries segment. Goodwill is primarily attributable to expected synergies enabling comprehensive support for customers in drug development, clinical trials, and product commercialization at scale. The majority of the goodwill is currently not expected to be deductible for income tax purposes. The results of operations were included in our consolidated financial results beginning on February 3, 2025. Pro forma information has not been provided as the acquisition of Pii is not deemed to be significant.
Read it in 10-K 2025-10-17 at sec.gov ↗
RemovedMD&A
On October 1, 2024, we completed the acquisition of Mikros Technologies LLC (“Mikros Technologies”) for consideration transferred of $63 million. Mikros Technologies is a leader in the engineering and manufacturing of liquid cooling solutions for thermal management. The final purchase price is subject to adjustment based on certain customary conditions as outlined in the purchase agreement.
Read it in 10-K 2025-10-17 at sec.gov ↗
RewordedMD&A
Payments due by period (in millions) Total Less than 1 1-3 years 3-5 years After 5 years year Notes payable and long-term debt $ 2,885 3,379 $ 499 $ 996 1,294 $ 795 1,094 $ 595 492 Future interest on notes payable and long-term debt(1) 322 99 148 68 7 425 133 180 79 33 Operating lease obligations(2) 594 112 165 118 199 obligations(2)(3) 785 138 228 167 252 Finance lease obligations(2)(3)(4) 422 208 65 30 119 377 99 116 52 110 Non-cancelable purchase order obligations(5) 625 313 254 58 623 388 204 31 — Pension and postretirement contributions and payments(6) 68 32 31 6 7 8 23 Total contractual obligations(7) $ 4,916 5,657 $ 1,263 1,288 $ 1,634 2,028 $ 1,076 1,431 $ 943 910
Read it in 10-K 2026-10-23 at sec.gov ↗
RewordedMD&A
The following Board approved share repurchase programs were executed through a combination of open market transactions and accelerated share repurchase (“ASR”) agreements and open market transactions (in millions):Board Approval Date Amount Authorized Shares Repurchased Total Cash Utilized Remaining Authorization Authorization Completion Date 2022 Share Repurchase Program Q4 FY 2021 $1,000 16.5 $1,000 $ — Q2 FY 2023 Amended 2023 Share Repurchase Program Q1 FY 2024 $2,500 20.4 $2,500 $ — Q1 FY 2025 2025 Share Repurchase Program Q1 FY 2025 $1,000 6.6 $1,000 $ — Q4 FY 2025 2023 2026 Share Repurchase Program Q1 FY 2023 $1,000 2.7 $224 (1) Q4 FY 2023 2026 Share Repurchase Program(2) Q4 FY 2025 $1,000 0.6 $135 4.0 $1,000 $ 865 — Q4 FY 2026 2027 Share Repurchase Program(1) Q4 FY 2026 $1,500 1.9 $602 $ 898
Read it in 10-K 2026-10-23 at sec.gov ↗
RewordedMD&A
Amortization of intangibles increased during the fiscal year ended August 31, 2025, 2026, compared to the fiscal year ended August 31, 2024, 2025, primarily due to (i) additional amortization associated with intangible assets related to the acquisitions of Mikros Technologies LLC Hanley, Rebound Technologies, and Pharmaceutics International, Inc. that occurred during the fiscal year ended August 31, 2025 and (ii) amortization related to the Green Point trade name, which was reclassified to a definite-lived intangible asset during the fiscal year ended August 31, 2024.
Read it in 10-K 2026-10-23 at sec.gov ↗
RewordedMD&A
Interest expense, net decreased increased during the fiscal year ended August 31, 2025, 2026, compared to the fiscal year ended August 31, 2024, 2025, primarily due to lower higher interest rates on fixed interest rate debt obligations, attributable to the issuance of 4.200% Senior Notes and lower borrowings primarily on our credit facilities and commercial paper program. 4.750% Senior Notes during the fiscal year ended August 31, 2026.
Read it in 10-K 2026-10-23 at sec.gov ↗
RewordedMD&A
Restructuring, severance Stock-based compensation expense and related charges decreased increased during the fiscal year ended August 31, 2025, 2026, compared to the fiscal year ended August 31, 2024, 2025, primarily due to higher restructuring, severance and related charges, related accelerated expense recognition associated with retirement provisions applicable to the 2024 Restructuring Plan, awards granted during the fiscal year ended August 31, 2024. 2026 and higher anticipated achievement levels for certain performance-based stock awards.
Read it in 10-K 2026-10-23 at sec.gov ↗
RewordedMD&A
Net cash used in investing activities during the fiscal year ended August 31, 2025, 2026, consisted primarily of the acquisition of Pharmaceutics International, Inc., Mikros Technologies, LLC Hanley and certain other third-party assets, Rebound Technologies and capital expenditures expenditures, principally to support ongoing business in the Regulated Industries, Intelligent Infrastructure, and Connected Living and Digital Commerce segments and the disposition of the Italy operations, segments, partially offset by proceeds and advances from the sale of property, plant and equipment and a working capital adjustment related to the divestiture of the Mobility Business. equipment.
Read it in 10-K 2026-10-23 at sec.gov ↗
RewordedMD&A
GAAP) $ 1,704 $ 1,182 $ 2,013 $ 1,537 Amortization of intangibles 89 62 40 33 Stock-based compensation expense and related charges 140 107 89 95 Restructuring, severance and related charges(1) 97 181 296 57 Net periodic benefit cost(2) cost 4 7 6 11 Business interruption and impairment charges, net(3) net(2) — 8 16 — Loss (gain) from the divestiture of businesses(4) businesses(3) 1 53 (942) — Acquisition and divestiture related charges charges(4) 34 20 70 — Adjustments to operating income 365 438 (425) 196 Core operating income (Non-GAAP) $ 2,069 $ 1,620 $ 1,588 $ 1,733 Net income attributable to Jabil Inc. Operating margin (U.S.
Read it in 10-K 2026-10-23 at sec.gov ↗
RewordedMD&A
Selling, general and administrative expenses decreased increased during the fiscal year ended August 31, 2025, 2026, compared to the fiscal year ended August 31, 2024. 2025, primarily due to an increase in salary and salary related expenses, including salary and salary related expenses resulting from the acquisitions of Hanley Energy Group (“Hanley”) and Rebound Technologies Group Holdings Limited (“Rebound Technologies”).
Read it in 10-K 2026-10-23 at sec.gov ↗
RewordedMD&A
Certain Additionally, certain post-closing adjustments associated with the divestiture of the Mobility Business were realized in March during the fiscal year ended August 31, 2025, which resulted resulting in the recognition of a $54 million pre-tax gain during the fiscal year ended August 31, 2025. gain.
Read it in 10-K 2026-10-23 at sec.gov ↗
RewordedMD&A
Certain Additionally, certain post-closing adjustments associated with the divestiture of the Mobility Business were realized in March during the fiscal year ended August 31, 2025, which resulted resulting in the recognition of a $54 million pre-tax gain during the fiscal year ended August 31, 2025. gain.
Read it in 10-K 2026-10-23 at sec.gov ↗
RewordedMD&A
During the three months ended August 31, 2025, 2026, the decrease increase in days in accounts receivable inventory from the prior sequential quarter and the three months ended August 31, 2024, 2025, was primarily driven by an increase in net revenue and the timing of payments. customer shipments in the Intelligent Infrastructure segment during the quarter.
Read it in 10-K 2026-10-23 at sec.gov ↗
RewordedMD&A
(i) a $17 million decrease in other selling, general lower salary and administrative salary related expenses primarily driven by the divestiture of the Mobility Business during the fiscal year ended August 31, 2024, (ii) a $10 million decrease in office and support costs, and (iii) a $7 million decrease due to lower salary and salary related expenses, and (iv) a $4 million decrease in business interruption and impairment charges, net.
Read it in 10-K 2026-10-23 at sec.gov ↗